Adverum Biotechnologies Inc. Daily Stock Analysis

Daily Stock Analysis, ADVM, Adverum Biotechnologies Inc, priceseries

Adverum Biotechnologies Inc. Daily Stock Analysis
Stock Information
Open
1.23
Close
1.27
High
1.30
Low
1.23
Previous Close
1.23
Daily Price Gain
0.04
YTD High
2.04
YTD High Date
Jan 3, 2022
YTD Low
1.23
YTD Low Date
Mar 7, 2022
YTD Price Change
-0.68
YTD Gain
-34.87%
52 Week High
11.59
52 Week High Date
Mar 10, 2021
52 Week Low
1.23
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-9.28
52 Week Gain
-87.96%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 8. 2017
2.80
Sep 25. 2017
3.23
11 Trading Days
15.50%
Link
LONG
Dec 18. 2017
3.20
Jan 9. 2018
3.87
14 Trading Days
21.03%
Link
LONG
Jan 16. 2018
4.35
Feb 6. 2018
6.59
15 Trading Days
51.50%
Link
LONG
Aug 17. 2018
5.20
Sep 6. 2018
6.59
13 Trading Days
26.80%
Link
LONG
Jan 31. 2019
3.18
Mar 8. 2019
4.42
25 Trading Days
38.91%
Link
LONG
Mar 11. 2019
4.70
Mar 25. 2019
5.45
10 Trading Days
16.05%
Link
LONG
Apr 18. 2019
5.98
May 8. 2019
6.54
13 Trading Days
9.40%
Link
LONG
May 16. 2019
8.13
Jun 14. 2019
10.85
20 Trading Days
33.45%
Link
LONG
Jul 3. 2019
11.62
Jul 18. 2019
14.31
10 Trading Days
23.17%
Link
LONG
Oct 14. 2019
6.09
Oct 30. 2019
6.97
12 Trading Days
14.40%
Link
LONG
Feb 10. 2020
12.05
Feb 24. 2020
14.23
9 Trading Days
18.12%
Link
LONG
Apr 16. 2020
11.62
Apr 22. 2020
12.23
4 Trading Days
5.25%
Link
LONG
May 4. 2020
13.73
May 13. 2020
17.62
7 Trading Days
28.30%
Link
LONG
Nov 19. 2020
12.68
Dec 4. 2020
13.74
10 Trading Days
8.32%
Link
LONG
Oct 28. 2021
2.10
Nov 11. 2021
2.24
10 Trading Days
6.51%
Link
Company Information
Stock Symbol
ADVM
Exchange
NasdaqGM
Company URL
http://www.adverumbio.com
Company Phone
650-272-6269
CEO
Amber Salzman
Headquarters
California
Business Address
1035 O'BRIEN DRIVE, MENLO PARK, CA 94025
Sector
-
Industry Category
-
Industry Group
-
CIK
0001501756
About

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Description

Avalanche Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading